MKI67 and ductal breast carcinoma in situ: Further research is needed to identify biomarkers that distinguish individuals at risk of DCIS recurrence from those at risk of developing invasive recurrence, to further evaluate the effect of joint expression of HER2/neu and Ki67 and of other combinations of biomarkers on the risks of local and invasive recurrence and to evaluate the effect of radiation on these outcomes.